ALMB-0166

DB17937InvestigationalProtein Based Therapies

ALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of acute spinal cord injury. It was granted FDA orphan designation in November 2018.

Mechanism: Pharmacologically active on Gap junction alpha-1 protein
Curator reviewed
Code names: ALMB-0166

Resolves to

Targets

P17302GJA1

What you can answer from here — as of August 06, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with ALMB-0166, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account